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Abstract
BACKGROUND: Cervical cancer was the fourth common women cancer in the world and the second most in 
Indonesia. Chemotherapy has been evaluated as a therapy strategy to treat cervical cancer stage IB2 and IIA2 prior 
the radical hysterectomy. Neoadjuvant chemotherapy was still being a controversy for the chemotherapy resistance 
patient and will delay the definitive therapy. A marker is needed to identify patient which more relatively resistant 
to chemotherapy. Squamous cell carcinoma (SCC) type was known to have a better response to neoadjuvant 
chemotherapy than non-SCC (nSCC) type, but they are no studies at Dr. M. Djamil Padang General Hospital yet on 
this matter before.
OBJECTIVE: The objectives of the study were to obtain the relationship between histopathology type and 
neoadjuvant chemotherapy response for cervical cancer stage IB2 and IIA2.
METHODS: This cohort analytic study conducted at Dr. M Djamil Padang Hospital which obtained 35 samples of 
stage IB2 and IIA2 cervical cancer patients whom treated with neoadjuvant chemotherapy. Results of histopathology 
are based on biopsy at diagnosis done for cervical cancer and chemotherapy response is based on transrectal 
ultrasound examinations before and after given neoadjuvant chemotherapy with response evaluation criteria in solid 
tumors criteria.
RESULTS: Complete response and partial response in the SCC and nSCC group were 32%–50%, while stable 
disease (SD) and progressive disease were 68% in the SCC group to 50% in the nSCC group.
CONCLUSION: There was no significant relationship between histopathological type and neoadjuvant chemotherapy 
response for cervical cancer stage IB2 and IIA2 (p = 0.44).
Background
Cervical cancer is a malignancy of cervix or 
uterus due to an abnormal changing and uncontrolled 
proliferation of cervical cells. The main etiology is 
by infection of one or more oncogenic types human 
papillomavirus and related to women who were married 
or sexually active [1], [2]. Cervical cancer was the fourth 
most common cancer in women in the world and took 
the second most cancer in 15–44-year-old women in 
the world [2].
National comprehensive cancer network 
(NCCN) guidelines recommended treatment 
modalities for this cancer type such as direct radical 
hysterectomy, radical surgery after neoadjuvant 
chemotherapy, and radiochemotherapy [3], [4], [5]. In 
1993, Sardi reported that neoadjuvant chemotherapy 
in IB2 type cervical cancer had a significant increase 
of survival rate and progression-free survival (PFS) 
after chemotherapy, especially in patients with tumor 
volume more than 60 dL [6], [7].
One of neoadjuvant chemotherapy combination 
from NCCN recommendation was paclitaxel with 
platinum (cisplatin or carboplatin). There were several 
reasons to use neoadjuvant chemotherapy to shrink 
the tumor size for facilitating surgery, reduce the rate of 
recurrence, and increase survival. However, in patients 
who were resistant to chemotherapy, it would delay the 
provision of definitive therapy, so important to find a 
marker to identify which patients were more resistant to 
chemotherapy relatively [8], [9].
Squamous cell carcinoma (SCC) had a better 
response to neoadjuvant chemotherapy than non-
squamous tumors. SCC patients not only had a better 
therapeutic response but also had tumor-free survival 
significantly better [10], [11].
Methods
This is a prospective cohort analytic study 
by observing histopathology type factors of cervical 
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cancer in patients with stage IB2 and IIA2 cervical 
cancer before neoadjuvant chemotherapy treatment 
and conducted from May 2018 until March 2019 at the 
Dr. M. Djamil Hospital Padang.
The target population was all stage IB2 and 
IIA2 cervical cancer patients in Dr. M. Djamil Hospital, 
who underwent neoadjuvant chemotherapy. The 
research sample done by a consecutive sampling 
technique. This study required 18 people as a 
minimal sample. The inclusion criteria of this study 
were patients who had diagnosed with stage IB2 and 
IIA2 cervical cancer who underwent neoadjuvant 
chemotherapy and willing to participate in research. 
The exclusion criteria of this study were patients who 
cannot perform transrectal ultrasound examination 
due to hemorrhoids, painful perianal, and anal 
stenosis and patients who cannot continue as the 
study sample (drop out).
Data were obtained from tumor measurements 
using transrectal ultrasound did by inserting the probe 
gently into the rectum, scanning uterus and adnexal 
region, measuring the tumor size in three dimensions of 
length (cm), height (cm), and width (cm) then calculated 
as tumor volume (cm3). Other data were anatomic 
pathology laboratory results.
Ultrasound transrectal reexamination was 
set 3 weeks after the last neoadjuvant chemotherapy 
regimen. Informed consent for reexamination was 
required before the examination. Reexamination did 
determine tumor size tumor clinically and measure 
tumor volume. Then, the measurements were classified 
to modified WHO criteria which divided into good 
response and poor response. Good response if tumor 
size reduction >50% from its original size and poor 
response when the tumor size reduction ≤50% of its 
original size.
Data of assessed variables were analyzed 
statistically using a computerized program in 
univariate and bivariate analysis. Univariate analysis 
aims to explain the characteristics of each studied 
variable and bivariate analysis aimed to examine the 
relationship between two variables in the research 
such tumor size and neoadjuvant chemotherapy 
response. In this study, bivariate analysis was 
conducted by the Chi-square test and independent 
sample t-test using Statistical Program for Social 
Science (SPSS) program.
Results
This study was conducted on 35 patients 
with stage IB2 and IIA2 cervical cancer disease in 
Dr. M. Djamil Hospital in Padang that fulfill the inclusion 
and exclusion criteria of the study.
Distribution of stage IB2 and IIA2 
cervical cancer patients frequency by 
histopathology type
The frequency distribution of stage IB2 and 
IIA2 cervical cancer patients by histopathology type 
showed in the following table:
Table 1 showed that from 35 study subjects, 
71.4% or 25 subjects had cervical cancer with SCC, 
the 28.6% remaining or 10 subjects had a non-SCC 
(nSCC) cancer type. Subject age at diagnosed of 
cervical cancer SCC of the type most commonly found 
in the age group 50–59 years (36%) followed by the 
age group above 60 years (24%), aged 40–49 years 
(28%), and 30–39 year (12%). While in the non-type 
cervical cancer SCC, the most prevalent age group 
was 40–49 years (50%) followed by the age group of 
50–59 and over 60 years (each 20%) and 30–39 year 
age group (10%).
Table 1: Characteristics of stage IB2 and IIA2 cervical cancer 
patients by histopathology type
Characteristic Squamous cell carcinoma Non-squamous cell carcinoma
F (%) F (%)
25 71.4 10 28.6
Age
30–39 3 12 1 10
40–49 7 28 5 50
50–59 9 36 2 20
≥60 6 24 2 20
Stages
IB2 10 40 6 60
IIA2 15 60 4 40
Stage IIA2 SCC subject was more than stage 
IB2 with 60% and 40% percentages, respectively. 
Otherwise, stage IA2 nSCC subject was more than 
stage IIB2, 60% and 40%, respectively.
Sample distribution by the WHO type of 
cervical cancer histopathology and chemotherapy 
response
The patient’s distribution by type of 
histopathology and chemotherapeutic responses was 
presented in the following Table 2 and ultrasound image 
of tumor size can be seen at Figure 1.
Table 2: Distribution for cervical cancer histopathology type 
and neoadjuvant chemotherapy response rate based on the 
WHO criteria
Histology type F % Chemotherapy response
Good Bad
Complete 
response (%)
Partial 
response (%)
Progressive 
disease (%)
Stable    
disease (%)
Squamous cell 
carcinoma
25 71.4 0 (0) 8 (32) 1 (4) 16 (68)
Non-keratinized 18 72 0 (0) 6 (33) 0 (0) 12 (67)
Poorly 5 20 0 (0) 2 (40) 0 (0) 3 (60)
Moderately 13 52 0 (0) 4 (30.8) 0 (0) 9 (69.2)
Keratinized 4 16 0 (0) 1 (25) 0 (0) 3 (75)
Papillary 2 8 0 (0) 1 (50) 0 (0) 1 (50)
Basaloid 
keratinized
1 4 0 (0) 0 (0) 1 (100) 0 (0)
Non-squamous 
cell carcinoma
10 28.6 0 (0) 5 (50) 0 (0) 5 (50)
Adenocarcinoma 8 80 0 (0) 4 (50) 0 (0) 4 (50)
Adenosquamous 1 10 0 (0) 1 (100) 0 (0) 0 (0)
Clear cell 1 10 0 (0) 0 (0) 0 (0) 1 (100)
Total 35 100 0 (0) 13 (37.15) 1 (2.85) 21 (60)
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From 35 patients, 25 (71.4%) had cervical 
cancer with SCC histopathology type, the remaining 
10 subjects (28.6%) had a type of cancer with nSCC. 
A total of 18 subjects (72%) SCC were a type of non-
keratinized (poorly 20% and moderately 52%), 4 (16%) 
subjects keratinized, 2 (8%) subjects types papillary, 
and 1 (4%) subjects the type of basaloid keratinized. 
While 10 subjects nSCC type consists of 8 (80%) 
subjects adenocarcinoma, and each one (10%) subjects 
adenosquamous and clear cell type.
SCC cervical cancer types that had a good 
response to chemotherapy were 32% or 8 subjects 
and all with partial response (PR) type well responses, 
while the subjects who responded poorly given more, 
16 subjects (68%). Of the 16 subjects, there was only 
one SCC subject who experienced with bad response 
type progressive disease, the remaining 15 subjects 
were type stable disease (SD). This same result was 
found in SCC keratinized (25% good and 75% bad). 
The papillary type has the same response between 
well and poorly. Instead, one subject with a keratinized 
basaloid type gave a bad response.
The nSCC types of cervical cancer were found 
in 10 subjects (28.6%). Adenocarcinoma was the most 
common histopathology type, 8 subjects (80%). The 
rest of the subjects was adenosquamous type and clear 
cell type. Of the 10 subjects, subjects that give a good 
or bad response to chemotherapy were same, 50%, 
respectively. Similarly, the type of SCC, the majority 
type of nSCC also provided good response type PR 
and type SD for a bad response. The same percentage 
also found in nSCC adenocarcinoma, where 50% 
gave a good response type PR and 50% gave a bad 
response type SD. All adenosquamous histopathology 
type provided good response types PR and clear cell 
types give a bad response type SD in all subjects.
Overall of 35 subjects, 37.15% gave a good 
response to neoadjuvant chemotherapy and 62.85% 
remaining gave a bad response to neoadjuvant 
chemotherapy.
Analysis of the relationship between type 
histopathology with neoadjuvant chemotherapy 
responses in stage IB2 and IIA2 cervical cancer
Analysis of the relationship between type 
histopathology with neoadjuvant chemotherapy 
responses in stage IB2 and IIA2 cervical cancer could 
be seen in the following Table 3.
Table 3: Analysis histologic type and neoadjuvant 
chemotherapy responses in cervical cancer stage IB2 and IIA2
Histology type Response chemotherapy criteria WHO p value
Baik Buruk
F % F %
Squamous cell carcinoma 8 32 17 68 0,44
Non-squamous cell carcinoma 5 50 5 50
According to the WHO criteria, this study found 
a good response to neoadjuvant chemotherapy that was 
32% in the group of SCC and 50% in the nSCC. Separated 
analysis for neoadjuvant chemotherapy response did not 
find any significant differences between all histopathologic 
types (p = 0.44), whereas the proportion (percentage) of 
neoadjuvant chemotherapy response relatively equally 
well on SCC or nSCC type cervical cancer.
Figure 1: Ultrasound examination before and after neoadjuvant 
chemotherapy
Bivariate analysis results were taken from 
Fisher’s exact test value that found no significant 
relationship between histopathology type with 
neoadjuvant chemotherapy response in IB2 and IIA2 
stages of cervical cancer.
Discussion
This study was conducted on 35 patients 
with IB2 and IIA2 stage cervical cancer that given 
neoadjuvant chemotherapy. This study was divided into 
two groups samples of 25 (71.4%) subjects had cervical 
cancer SCC histopathology type and the remaining 
10 (28.6%) subjects had a type of cancer with nSCC. 
The most common subject age at diagnosed cervical 
cancer with SCC type found in the age group 50–59 
years (36%) followed by the age group above 60 years 
(24%), aged 40–49 years (28%), and 30–39 year (12%). 
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While in the non-type cervical cancer, SCC was most 
prevalent in the age group 40–49 years (50%) followed 
by the age group of 50–59 and over 60 years (each 
20%) and 30–39 year age group (10%). This was in line 
with research conducted by Prandana et al. (2013) that 
found the majority of cervical cancer patients was in 
the age group of 40–55 years of 214 patients (58.3%), 
followed by cervical cancer by age group >55 years, 
101 patients (27.5%) [33]. Another study conducted 
by Haryani (2014) at Dr. M. Djamil Hospital in Padang 
showed that the highest incidence of cervical cancer 
was in >50 years age group, 27 people (42.9%) [34].
Risk of cervical cancer increases with age 
developments. It is associated with increased frequency 
and duration of exposure to carcinogens and weakening 
the immune system that plays a role in destroying 
cancer cells, thereby slowing the progression and 
spreading. It required about 10–20 years for becoming 
invasive cancer [55].
Lack of awareness for screening or lack of 
access and treatment was causing the patients came 
for treatment at an advanced stage, while the advanced 
stage was the main cause for increased morbidity 
and mortality in cervical cancer [56], [57]. Stage IIA2 
SCC subject was more than stage IB2, 60% and 40%, 
respectively. In other hands, stage IA2 in nSCC subject 
was more than stage IIB2, 60% and 40%, respectively. 
Research Khatun et al. (2016) also found 38 cervical 
cancer patients with SCC types, 31 patients were in 
stage IB2 and 7 patients were in stage IIA2 [9].
Research by Osman found of 1760 his research 
subject populations, patients with stage IB2-IIA cervical 
cancer were the most by 1230 patients (69.8%) followed 
by IIB–IIIA of 335 patients (19.2%). The average of 
stage IB2–IIA 2-year PFS was 79.1% and 2-year overall 
survival (OS) was 86%, while the average for a 5-year 
PFS was 72% and 5-year OS was 83.4% [56].
The most histopathology type was SCC which 
by around 80%, followed by adenocarcinoma by 20%, 
and the others were rare [47]. A study conducted in 
Bandung Al-Ihsan Hospitals (2017) had 58 people 
(70.7%) with SCC of 82 total samples. Other supporting 
results were also found by previous research at Dr. 
Zainoel Abidin in Banda Aceh (2012) that obtained 
17 (77.28%) of 22 subjects were cervical cancer 
with SCC histopathological type [55] Research at Dr. 
Sardjito Hospital (2016), of 105 patients with cervical 
cancer, 72.38% (76 cases) were cervical cancer with a 
histopathological type of SCC.
Nuranna et al. (2006) found that 320 cases 
(71.6%) of 447 cases of cervical cancer were SCC type 
[43]. Osman conducted research with 1760 total cases, 
he found about 1680 cases (95.4%) belong to the SCC 
group, and 55 cases (3.1%) were adenocarcinoma [33]. 
Endo in 2011 stated that of 85 patients with cervical 
cancer, 76 patients (89%) were SCC group [38]. 
These findings were in line with Bogani et al. (2017), 
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from 275 patients, about 221 patients (80%) had SCC 
histopathology type [40]. So did Alcázar et al. that 
obtained 49 (83.9%) from 56 cases of tumors were SCC, 
and 9 other cases (16.1%) were adenocarcinoma [42].
Relationship between histopathology 
type and neoadjuvant chemotherapy response in 
stages IB2 and IIA2 cervical cancer
This research found that there was no statistically 
significant relationship between histopathology type 
and neoadjuvant chemotherapy response. Subject 
percentage with good response to neoadjuvant 
chemotherapy in this study according to the WHO criteria 
was 32% in the SCC group and 50% in nSCC. After 
the data were analyzed separately, we did not find any 
significant differences between each histopathology type 
statistically (p = 0.44), where the proportion (percentage) 
of neoadjuvant chemotherapy response was relative 
equally well in each type of SCC or nSCC cancer.
There were no other studies which found 
similar results to this study. It has generally known 
that SCC provides a good response to neoadjuvant 
chemotherapy. This study was out of line with research 
by Serur et al. that found IB2 cervical cancer with SCC 
was claimed as the most population about 18/20 (90%) 
got a well response to neoadjuvant chemotherapy 
[43]. Moreover, He et al. mentioned that SCC provided 
a good response to neoadjuvant chemotherapy as 
much as 80.2% and non-squamous tumors gave a 
good response to chemotherapy, only about 75.1% 
[58]. Then, the 5-year survival rate of SCC was better 
than non-squamous tumor patients [44]. Otherwise, this 
study’s found diverse results, even though not significant 
statistically, nSCC had a better response than SCC.
Neoadjuvant chemotherapy response was 
influenced by various factors, namely, the stage and 
type of histopathology. A study conducted by Piu 
et al. stated that SCC provides a better response 
to neoadjuvant chemotherapy than non-squamous 
tumors. In this study, a total of 63/103 (61.2%) patients 
had a good respond to neoadjuvant chemotherapy [3], 
[4]. A study by Wang et al. (2014) stated that as many 
as 93.4% of patients with SCC histopathology type 
gave a good response to neoadjuvant chemotherapy 
and only 75% adenocarcinoma patients respond well to 
chemotherapy neoadjuvant [45].
Modares et al. (2004) conducted a study to 30 
cervical cancer patients that treated with neoadjuvant 
chemotherapy; about 27/30 (90%) patients had 
SCC type. All 30 samples gave a good response to 
chemotherapy neoadjuvant [46]. 
The use of chemotherapy drugs that have 
been properly can improve the results of neoadjuvant 
chemotherapy too. Research have found a significant 
difference of operability in SCC cervical cancer 
patients whom treated with chemotherapy paclitaxel 
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and carboplatin compared to chemotherapy cisplatin, 
vincristine, and bleomycin [43].
Research limitations
1. This study was a cohort analytic study that 
takes long waiting time for the patient returned 
to control for the second assessment
2. This research focused on the relationship 
between histopathologic type and response for 
neoadjuvant chemotherapy in cervical cancer 
stage IB2 and IIA2, but other factors have not 
been analyzed
3. Exclusion criteria lessen submitted research 
samples.
Conclusion
1. There was no significant relationship between 
histopathology type and neoadjuvant 
chemotherapy response in nSCC and SCC, 
where the chemotherapy neoadjuvant 
response relatively equally well on each type 
of SCC or nSCC cancer
2. In general, stage 1B2 and IIA2 cervical cancer 
patients had a good response to neoadjuvant 
chemotherapy.
Suggestion
1. Stage IB2 and IIA2 cervical cancer can treat 
with neoadjuvant chemotherapy as one of the 
promising therapeutic alternatives
2. Further research about other factors that affect 
the response of neoadjuvant chemotherapy is 
needed, as a degree of tumor differentiation 
and tumor vascularization factors.
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